Biohaven Ltd. (NYSE:BHVN) Given Average Rating of “Moderate Buy” by Brokerages

Biohaven Ltd. (NYSE:BHVN) has been assigned an average rating of “Moderate Buy” from the seventeen analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $18.6875.

Several equities research analysts have weighed in on BHVN shares. TD Cowen reissued a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. Raymond James Financial reiterated a “strong-buy” rating and issued a $30.00 target price on shares of Biohaven in a report on Wednesday, August 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a research report on Friday, August 28th. Morgan Stanley increased their price target on Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $21.00 price target on Biohaven in a research report on Friday, August 28th.

Biohaven Trading Down 2.3%

BHVN stock opened at $13.58 on Friday. The firm has a fifty day moving average price of $14.41 and a 200 day moving average price of $12.16. Biohaven has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The firm has a market cap of $2.05 billion, a PE ratio of -2.93 and a beta of 1.28. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts anticipate that Biohaven will post -3.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biohaven

Several institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after purchasing an additional 16,127,247 shares during the last quarter. BlackRock Inc. bought a new stake in Biohaven in the second quarter worth about $196,574,000. Jupiter Topco LLC bought a new stake in Biohaven in the second quarter worth about $127,852,000. Stempoint Capital LP bought a new stake in Biohaven in the first quarter worth about $13,489,000. Finally, Vanguard Group Inc. boosted its position in shares of Biohaven by 52.9% during the fourth quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after buying an additional 1,520,756 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options.

Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases.